Nanopore Targeted Sequencing for Suspected Bloodstream Infections: Pathogen Detection, Diagnostic Performance, and Potential Impact on Antimicrobial Management
In brief
Nanopore sequencing detects 73% of bloodstream infections, versus 47% with cultures
In this retrospective study of 238 patients, nanopore sequencing was more sensitive than blood cultures for clinically diagnosed bloodstream infections, and combining both tests raised sensitivity to 84%. Most sequencing results were estimated within 6.3 hours, but the single-center design and possible incorporation bias could make performance look better than it is; treatment changes were assessed in a small, non-randomized subgroup.
- Journal
- Infection and drug resistance (Q2)
- Published
- 14 November 2026
- Study design
- Non-randomized / quasi-experimental trial
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Dong Wang, Hui Wang, Luo Yang, Rui Liao, Tao Fang, Dan Zhang
- PMID
- 43054940
- DOI
- 10.2147/IDR.S652942
Why clinicians should know about it
- Picked for Microbiology (medical) (top studies of the week, 22 November 2026): Compares rapid nanopore pathogen detection with blood culture and turnaround
Abstract
BACKGROUND: Rapid and accurate pathogen identification is essential for the management of bloodstream infection (BSI), but blood culture (BC) has limitations in detection yield and turnaround time. We evaluated the complementary value of nanopore targeted sequencing (NTS) alongside BC in patients with suspected BSI, focusing on pathogen detection, diagnostic performance, and antimicrobial management. METHODS: This single-center retrospective cohort study included 238 patients who underwent NTS and BC within a 24-hour sample-submission interval. Diagnostic performance was assessed against the final clinical diagnosis documented during routine care, with viral detections excluded when defining NTS positivity. Paired positivity rates and sensitivities were compared using two-sided exact McNemar tests. NTS laboratory turnaround time (TAT) and antimicrobial management were summarized descriptively. RESULTS: BSI was clinically diagnosed in 62 patients (26.1%). Overall positivity was higher for NTS than BC (31.9% [76/238] versus 12.2% [29/238]; P < 0.001), and remained higher after excluding viral detections (19.3% [46/238] versus 12.2% [29/238]; P = 0.0033). Sensitivity was 72.6% for NTS and 46.8% for BC (P = 0.0052). Specificity was 99.4% and 100%, respectively, with one false-positive NTS result versus none for BC. Positive predictive value (PPV) and negative predictive value (NPV) were 97.8% and 91.1% for NTS, compared with 100% and 84.2% for BC. The combined strategy, defined as positive if either test was positive, yielded sensitivity, specificity, PPV, and NPV of 83.9%, 99.4%, 98.1%, and 94.6%, respectively. The estimated NTS laboratory TAT was approximately 6.3 h for 80% of samples. In the non-randomized management subgroup of 53 patients, decisions were reported as NTS-informed in 33 and BC-informed in 20. De-escalation, escalation, and no change occurred in 9/33 (27.3%), 11/33 (33.3%), and 13/33 (39.4%) in the NTS-informed group, respectively. Corresponding figures in the BC-informed group were 4/20 (20.0%), 9/20 (45.0%), and 7/20 (35.0%). CONCLUSION: NTS showed higher pathogen detection positivity and diagnostic sensitivity than BC, with a short estimated laboratory TAT. Combining NTS with BC increased sensitivity, supporting their complementary use. NTS may also provide clinically actionable microbiological information to support antimicrobial treatment adjustment. Diagnostic performance estimates may be optimistic because of potential incorporation bias.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.